RNA-based nanoparticle treatment shows promise in Ewing's sarcoma model.
Hede
Karyn
K
D000818:Animals; D001859:Bone Neoplasms / Q000235:genetics* / Q000378:metabolism; D045744:Cell Line, Tumor; D002482:Cellulose; D003505:Cyclodextrins; D004195:Disease Models, Animal; D015972:Gene Expression Regulation, Neoplastic; D051379:Mice; D049329:Nanostructures; D015514:Oncogene Proteins, Fusion / Q000187:drug effects; D034741:RNA, Small Interfering / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D034802:RNA-Binding Protein EWS / Q000187:drug effects*; D011990:Receptors, Transferrin / Q000187:drug effects / Q000378:metabolism; D012512:Sarcoma, Ewing / Q000235:genetics* / Q000378:metabolism; D015854:Up-Regulation
D003505:Cyclodextrins; D015514:Oncogene Proteins, Fusion; D034741:RNA, Small Interfering; D034802:RNA-Binding Protein EWS; D011990:Receptors, Transferrin; C041953:cyclodextrin polymer; D002482:Cellulose